Kintara Therapeutics, Inc. (NASDAQ:KTRA) Short Interest Up 320.9% in September

Kintara Therapeutics, Inc. (NASDAQ:KTRA) was the target of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 5,430,000 shares, a growth of 320.9% from the September 15th total of 1,290,000 shares. Based on an average daily trading volume, of 2,860,000 shares, the short-interest ratio is presently 1.9 days.

Kintara Therapeutics Price Performance

Shares of KTRA stock remained flat at $0.18 during trading hours on Friday. 355,523 shares of the stock were exchanged, compared to its average volume of 10,097,389. The business has a 50 day moving average of $0.19 and a two-hundred day moving average of $0.19. Kintara Therapeutics has a 52-week low of $0.08 and a 52-week high of $4.59.

Kintara Therapeutics Company Profile

Kintara Therapeutics, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients.